Cipla, Piramal Launch Sensipar Generics Amid Growing Antitrust Challenges to Amgen/Teva Settlement
Amgen seeks a preliminary injunction to halt US sales by Cipla and says it will take steps to stop Piramal’s sales; in its antitrust lawsuit, Cipla alleges Amgen paid to license Teva products under the companies’ patent settlement, which resulted in Teva pulling its generic off the market shortly after launch.
You may also be interested in...
Dissecting Piramal’s Damages Award In Sensipar Case
A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.
Cipla And Amgen Agree To Settle On Sensipar
Cipla launched its generic version of Amgen’s Sensipar ‘at risk’ in March last year after suing the originator and Teva over an earlier agreement between the pair. The suit has now been settled, although claims against Teva remain standing.
Amgen Fails To Block Cipla’s Generic Cinacalcet In US, And It May Change How Patent Settlements Are Drafted
Amgen is unlikely to succeed on the merits of its breach of contract claim, court says, concluding that Teva’s December launch of its noninfringing generic precludes the Sensipar marketer from seeking recovery for Cipla’s at-risk launch under the Amgen-Cipla settlement agreement.